ArticleBMC cancer2025
Three-year survival outcomes following radical hysterectomy in early-stage cervical carcinoma: A study at Bugando medical centre, Mwanza, Tanzania.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadical hysterectomy, the surgical removal of the uterus, cervix, upper vagina, parametria, and associated tissues, along with bilateral pelvic lymph node dissection, is the global gold standard for treating early-stage cervical carcinoma. Over 110 early-stage cervical cancer patients have undergone this procedure at our institution for the past 10 years. However, data on long-term survival outcomes in the region remain unavailable. Including this information highlights the scale of the institution's experience, adding valuable context to the study. This study evaluates the institution's performance since adopting the procedure and aims to inform patient selection and treatment strategies, leveraging insights from studies conducted in varied clinical settings.
methodsThis retrospective cohort study analyzed women who underwent radical hysterectomy for early-stage cervical cancer (IB1-IIA2) at Bugando Medical Centre (2014-2020). Data were collected from patient charts, including demographics, histology, clinical stage, surgical details, therapies, and follow-up outcomes. Patients with incomplete procedures, histology, or follow-up data were excluded. Data analysis, performed using Epi Info™ and STATA version 13, included survival probabilities calculated by the Kaplan-Meier method and group comparisons using the log-rank test. Descriptive statistics summarized patient characteristics, and chi-square tests analyzed categorical variables. A p-value of < 0.05 was considered statistically significant.
results86 patients were reviewed, with the majority (80.2%) being under 60 years of age and a mean age of 51 ± 10.0 years. The 3-year overall survival rate was 96.5%, disease-free survival was 79.1%, and the recurrence rate was 20.9%. Factors significantly associated with 3-year disease recurrence included: tumour size ≥ 4 cm (log-rank χ²(1) = 19.53, p < 0.001), poorly differentiated tumour grade (log-rank χ²(2) = 11.27, p = 0.004), adenocarcinoma histology (log-rank χ²(1) = 18.79, p < 0.001), vaginal vault involvement (log-rank χ²(1) = 83.03, p < 0.001), and surgical margin involvement (log-rank χ²(1) = 67.81, p < 0.001). No significant association was found between the mode of treatment (neoadjuvant, surgery alone, or adjuvant) and disease recurrence (p = 1.553).
conclusionThe 3-year overall survival rate following radical hysterectomy was 96.5%, with a recurrence rate of 20.9%. Factors associated with recurrence included tumour size ≥ 4 cm, poorly differentiated tumour grade, adenocarcinoma histology, vaginal vault involvement, and positive surgical margins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.